



Appendix 4C – Quarterly Cash Flow Report

- **Cash position \$2.9m**
- **R&D tax refund for 2017 expected in quarter ending June 2018**

Melbourne, Australia, 30 April 2018: Sienna Cancer Diagnostics Ltd (ASX:SDX) (“Sienna” or “The Company”), a medical technology company developing and commercialising innovative cancer-related tests, is pleased to release its Appendix 4C – Quarterly Cash Flow Report for the quarter ended 31 March 2018.

The Company ended the quarter with a cash balance of \$2.9 million. Product orders were received in each month of the quarter. An inter-bank communication problem prevented the receipt of funds for our US distributor’s (StatLab) January order during the quarter. The issue was resolved and the funds were received in early April. Payments for the February and March orders are due to be received in the quarter ending 30 June 2018.

Following the lodgement of its 2017 R&D Tax Incentive application, Sienna expects to receive the R&D tax refund in the quarter ending June 2018.

StatLab no longer sells to Bostwick Laboratories as a result of the acquisition of Bostwick by Poplar Healthcare and the closing of Bostwick’s New York operations. Sienna expects that all future USA-based revenues will be generated through laboratories engaged and established as customers of StatLab, including Poplar Healthcare.

During the quarter, Sienna continued to progress the Company’s strategic growth initiatives, including the additional application and geographical expansion programs for the in-vitro diagnostic test for hTERT. Considerable work has also been carried out in pursuit of the product pipeline expansion program.

- ENDS -

For further information, please contact:

Matthew Hoskin, CEO
Sienna Cancer Diagnostics
mhoskin@siennadiagnostics.com.au
+61 3 8288 2141

Kyahn Williamson
WE Buchan
kwilliamson@we-buchan.com
+61 3 9866 4722

About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd. is an Australian medical technology company, with operations in the United States, Europe and Australia. Sienna’s strengths lie in identifying novel technologies that satisfy an unmet clinical / market need, then developing and commercialising them. The Company has demonstrated the utility of its first product with the help of its global clinical partners. Sienna’s primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009. Telomerase is well recognised as an important biomarker used by 85% of cancers to enable immortal cell replication.

The FDA listing of Sienna’s first IVD in the United States, and CE marking / IVD registration in Europe and Australia, means the hTERT test can be used for clinical diagnostic purposes by pathology laboratories in those regions.

Forward Looking Statements

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Sienna Cancer Diagnostics Limited

ABN

74 099 803 460

Quarter ended ("current quarter")

31 March 2018

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	4	370
1.2 Payments for		
(a) research and development	(59)	(108)
(b) product manufacturing and operating costs	-	(26)
(c) advertising and marketing	(80)	(136)
(d) leased assets		
(e) staff costs	(445)	(1,263)
(f) administration and corporate costs	(132)	(967)
1.3 Dividends received (see note 3)		
1.4 Interest received	19	49
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	(693)	(2,081)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	(14)
(b) businesses (see item 10)		
(c) investments		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
(d) intellectual property	(12)	(28)
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
2.6 Net cash from / (used in) investing activities	(12)	(42)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	4,598
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options	-	(335)
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities	-	4,263

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	3,563	721
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(693)	(2,081)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	(12)	(42)
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	4,263

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.5	Effect of movement in exchange rates on cash held	-	(3)
4.6	Cash and cash equivalents at end of quarter	2,858	2,858

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	758	862
5.2	Call deposits	2,100	2,701
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,858	3,563

6. Payments to directors of the entity and their associates

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Current quarter \$A'000
48
-

Remuneration payments to Non-executive Directors.

7. Payments to related entities of the entity and their associates

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

Current quarter \$A'000
-
-

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities		
8.2 Credit standby arrangements	20	2
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

Relates to the corporate credit card facility with the National Australia Bank.

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	(50)
9.2 Product manufacturing and operating costs	
9.3 Advertising and marketing	(80)
9.4 Leased assets	-
9.5 Staff costs	(450)
9.6 Administration and corporate costs	(250)
9.7 Other (provide details if material)	(25)
9.8 Total estimated cash outflows	(855)

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:  Date:30 April 2018.....
(Company secretary)

Print name: ..Tony Di Pietro.....

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.